Reviva Pharmaceuticals (RVPH) Competitors $0.40 -0.01 (-1.51%) Closing price 04:00 PM EasternExtended Trading$0.40 +0.00 (+1.23%) As of 05:21 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock RVPH vs. ANEB, PYXS, ADAP, PYRGF, VRCA, CNTB, STRO, IKNA, ANRO, and CLSDShould you be buying Reviva Pharmaceuticals stock or one of its competitors? The main competitors of Reviva Pharmaceuticals include Anebulo Pharmaceuticals (ANEB), Pyxis Oncology (PYXS), Adaptimmune Therapeutics (ADAP), PyroGenesis Canada (PYRGF), Verrica Pharmaceuticals (VRCA), Connect Biopharma (CNTB), Sutro Biopharma (STRO), Ikena Oncology (IKNA), Alto Neuroscience (ANRO), and Clearside Biomedical (CLSD). These companies are all part of the "pharmaceutical products" industry. Reviva Pharmaceuticals vs. Its Competitors Anebulo Pharmaceuticals Pyxis Oncology Adaptimmune Therapeutics PyroGenesis Canada Verrica Pharmaceuticals Connect Biopharma Sutro Biopharma Ikena Oncology Alto Neuroscience Clearside Biomedical Anebulo Pharmaceuticals (NASDAQ:ANEB) and Reviva Pharmaceuticals (NASDAQ:RVPH) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, analyst recommendations, valuation, dividends, risk, profitability, earnings and media sentiment. Which has more volatility & risk, ANEB or RVPH? Anebulo Pharmaceuticals has a beta of -0.98, meaning that its share price is 198% less volatile than the S&P 500. Comparatively, Reviva Pharmaceuticals has a beta of -0.06, meaning that its share price is 106% less volatile than the S&P 500. Does the media prefer ANEB or RVPH? In the previous week, Anebulo Pharmaceuticals had 1 more articles in the media than Reviva Pharmaceuticals. MarketBeat recorded 1 mentions for Anebulo Pharmaceuticals and 0 mentions for Reviva Pharmaceuticals. Reviva Pharmaceuticals' average media sentiment score of 1.87 beat Anebulo Pharmaceuticals' score of 0.93 indicating that Reviva Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Anebulo Pharmaceuticals Positive Reviva Pharmaceuticals Very Positive Do analysts prefer ANEB or RVPH? Anebulo Pharmaceuticals currently has a consensus price target of $5.50, suggesting a potential upside of 235.37%. Reviva Pharmaceuticals has a consensus price target of $9.00, suggesting a potential upside of 2,155.07%. Given Reviva Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Reviva Pharmaceuticals is more favorable than Anebulo Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Anebulo Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00Reviva Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 5 Buy rating(s) 2 Strong Buy rating(s) 3.29 Which has better earnings and valuation, ANEB or RVPH? Anebulo Pharmaceuticals is trading at a lower price-to-earnings ratio than Reviva Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioAnebulo PharmaceuticalsN/AN/A-$8.20M-$0.26-6.31Reviva PharmaceuticalsN/AN/A-$29.92M-$0.79-0.51 Is ANEB or RVPH more profitable? Reviva Pharmaceuticals' return on equity of 0.00% beat Anebulo Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Anebulo PharmaceuticalsN/A -90.11% -84.53% Reviva Pharmaceuticals N/A N/A -302.31% Do insiders and institutionals have more ownership in ANEB or RVPH? 28.4% of Anebulo Pharmaceuticals shares are owned by institutional investors. Comparatively, 63.2% of Reviva Pharmaceuticals shares are owned by institutional investors. 80.6% of Anebulo Pharmaceuticals shares are owned by insiders. Comparatively, 27.2% of Reviva Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term. SummaryReviva Pharmaceuticals beats Anebulo Pharmaceuticals on 9 of the 14 factors compared between the two stocks. Get Reviva Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RVPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RVPH and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RVPH vs. The Competition Export to ExcelMetricReviva PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$19.16M$2.43B$5.50B$9.41BDividend YieldN/A1.79%3.80%4.05%P/E Ratio-0.519.0528.0619.83Price / SalesN/A711.42431.6999.53Price / CashN/A161.2635.8457.94Price / Book19.965.008.125.65Net Income-$29.92M$30.99M$3.25B$257.88M7 Day Performance2.02%1.73%1.05%2.06%1 Month Performance-40.79%9.25%7.44%11.06%1 Year Performance-63.05%-1.12%31.46%18.45% Reviva Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RVPHReviva Pharmaceuticals3.3882 of 5 stars$0.40-1.5%$9.00+2,155.1%-66.1%$19.16MN/A-0.515Positive NewsGap UpANEBAnebulo Pharmaceuticals2.4476 of 5 stars$1.65-2.1%$5.50+234.3%-27.8%$69.02MN/A-6.334News CoverageGap DownHigh Trading VolumePYXSPyxis Oncology2.4304 of 5 stars$1.14+3.6%$9.00+689.5%-64.2%$68.14MN/A-0.7260ADAPAdaptimmune Therapeutics1.8155 of 5 stars$0.24-3.6%$1.35+460.6%-78.1%$66.26M$178.03M-0.89490Gap DownPYRGFPyroGenesis Canada0.0907 of 5 stars$0.35+4.0%N/A-51.6%$66.16M$9.14M-5.9190Gap UpVRCAVerrica Pharmaceuticals4.4058 of 5 stars$0.83+17.4%$8.00+863.9%-89.2%$65.36M$7.57M-0.6940CNTBConnect Biopharma2.6238 of 5 stars$1.14-2.5%$7.00+514.0%+44.2%$64.97M$26.03M0.00110News CoverageSTROSutro Biopharma4.2031 of 5 stars$0.74-2.9%$6.11+725.4%-81.1%$64.46M$62.04M-0.25240IKNAIkena Oncology2.8041 of 5 stars$1.35+1.5%$3.00+122.2%-25.9%$64.18M$9.16M-1.5770ANROAlto Neuroscience1.922 of 5 stars$2.30-2.1%$8.50+269.6%-82.1%$63.62MN/A-0.98N/ACLSDClearside Biomedical2.3812 of 5 stars$0.82+0.3%$4.75+482.8%-50.3%$63.12M$1.66M-1.9930Trending NewsAnalyst DowngradeGap Down Related Companies and Tools Related Companies ANEB Alternatives PYXS Alternatives ADAP Alternatives PYRGF Alternatives VRCA Alternatives CNTB Alternatives STRO Alternatives IKNA Alternatives ANRO Alternatives CLSD Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RVPH) was last updated on 7/18/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredI was wrong about TrumpI made a mistake. A mistake I feel very foolish about. After speaking with Donald Trump and some of his ...Porter & Company | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Reviva Pharmaceuticals Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Reviva Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free RVPH Stock Alerts